Over the past decade, there have been advances in clinical outcomes and prognosis data on Janus Kinase (JAK) inhibitors. 1,2 Despite this, there is a constant need to develop novel drugs for the successful treatment of patients with rheumatoid arthritis (RA). 1 Baricitinib is a targeted synthetic disease-modifying antirheumatic drug (tsDMARD). It selectively inhibits JAK1/JAK2- the primary enzymes involved in RA pathogenesis. 1 The oral form and fast action of Baricitinib make it a game-changer in rheumatic disease management. 2 In this regard, Eli Lilly and Docplexus have organized an interactive webinar on 16 th October 2020 at 8:00 PM (IST) .
In this LIVE session, Dr. Sharath Kumar , Dr. Vijay Rao , Dr. Sunil Singh , and Dr. Neeraj Jain will discuss the ‘Journey Of 2 Years In India: Real Life Experiences’ . Agenda: We invite you to share your queries, which will be…
